Keppra 100mg Syrup contains Levetiracetam at a concentration of 100mg/ml and is an antiepileptic medication indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam’s exact mechanism of action is not fully understood; however, it is believed to modulate synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby inhibiting abnormal neuronal excitability. Keppra Syrup offers a convenient oral liquid formulation suitable for pediatric patients and individuals who have difficulty swallowing tablets. The recommended dosage varies based on patient age, weight, and clinical response, and should be titrated carefully to minimize adverse effects. Common side effects include somnolence, dizziness, headache, and behavioral changes such as irritability or agitation. Keppra is generally well-tolerated and has a favorable pharmacokinetic profile with minimal drug interactions. It is important to adhere strictly to prescribed dosing and not discontinue therapy abruptly to avoid seizure exacerbation. Keppra 100mg Syrup should be used under medical supervision, with regular monitoring to assess therapeutic efficacy and tolerability. Caution is advised in patients with renal impairment, and dosage adjustments may be necessary.